Literature DB >> 33107563

Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location.

Anthony Buisson1,2,3, Wing Yan Mak1,4, Michael J Andersen1, Donald Lei1, Joel Pekow1, Russell D Cohen1, Stacy A Kahn5, Bruno Pereira6, David T Rubin1.   

Abstract

BACKGROUND: As the reliability of fecal calprotectin (Fcal) remains debatable to detect endoscopic ulcerations in patients with pure ileal Crohn's disease (CD), we aimed to compare its performances with those observed in patients with colonic or ileocolonic location.
METHODS: Using a prospectively maintained database, we analyzed 123 CD patients with Fcal measurement and ileocolonoscopy performed within 1 month with no therapeutic intervention during this interval. Receiver operating characterstic curves (ROC) were used to determine the best Fcal threshold to detect endoscopic ulcerations, taking into account the clinical relevance and usual recommended indices. Sensitivity, specificity, and positive (PPV) and negative predictive values (NPV) were presented with 95% confidence intervals.
RESULTS: The mean Fcal level was significantly higher in patients with endoscopic ulcerations in the L1 group (P = 0.025) and the L2-L3 group (P < 0.001). Using ROC curves, Fcal >200 µg/g and Fcal >250 µg/g were the best thresholds to detect endoscopic ulcerations in the L1 group (sensitivity = 75.0, 95% CI, 47.6-92.7; specificity = 87.5, 95% CI, 67.6-97.3; PPV = 80.0, 95% CI, 51.9-95.7; and NPV = 84.0; 95% CI, 63.9-95.5) and in the L2-L3 group (sensitivity = 84.1 95% CI, 69.9-93.4; specificity = 74.4, 95% CI, 57.9-87.0; PPV = 78.7, 95% CI, 64.3-89.3, and NPV = 80.6, 95% CI, 64.0-91.8), respectively. We compared the AUC between L1 and L2-L3 groups, and no difference was shown (0.89 vs 0.84, respectively, P = 0.46). We also compared 2-by-2 sensitivity, specificity, PPV, NPV, and accuracy and we did not observe any significant difference.
CONCLUSION: Fecal calprotectin is highly effective to detect endoscopic ulcerations regardless of CD location but requires a lower cutoff value in patients with pure ileal involvement.
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; biomarker; fecal calprotectin; mucosal healing

Mesh:

Substances:

Year:  2021        PMID: 33107563      PMCID: PMC8600021          DOI: 10.1093/ibd/izaa269

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   7.290


  34 in total

1.  Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease.

Authors:  F Goutorbe; M Goutte; R Minet-Quinard; A-L Boucher; B Pereira; G Bommelaer; A Buisson
Journal:  J Crohns Colitis       Date:  2015-09-07       Impact factor: 9.071

2.  A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence.

Authors:  Elena Cerrillo; Inés Moret; Marisa Iborra; José Pamies; David Hervás; Luis Tortosa; Esteban Sáez-González; Pilar Nos; Belén Beltrán
Journal:  Inflamm Bowel Dis       Date:  2019-09-18       Impact factor: 5.325

3.  Impact of disease location on fecal calprotectin levels in Crohn's disease.

Authors:  Krisztina B Gecse; Johannan F Brandse; Sandra van Wilpe; Mark Löwenberg; Cyriel Ponsioen; Gijs van den Brink; Geert D'Haens
Journal:  Scand J Gastroenterol       Date:  2015-01-30       Impact factor: 2.423

4.  Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease.

Authors:  Gilles Boschetti; Marc'harid Laidet; Driffa Moussata; Carmen Stefanescu; Xavier Roblin; Gildas Phelip; Eddy Cotte; Guillaume Passot; Yves Francois; Jocelyne Drai; Emilie Del Tedesco; Yoram Bouhnik; Bernard Flourie; Stephane Nancey
Journal:  Am J Gastroenterol       Date:  2015-03-17       Impact factor: 10.864

5.  Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.

Authors:  Emily K Wright; Michael A Kamm; Peter De Cruz; Amy L Hamilton; Kathryn J Ritchie; Efrosinia O Krejany; Steven Leach; Alexandra Gorelik; Danny Liew; Lani Prideaux; Ian C Lawrance; Jane M Andrews; Peter A Bampton; Simon L Jakobovits; Timothy H Florin; Peter R Gibson; Henry Debinski; Finlay A Macrae; Douglas Samuel; Ian Kronborg; Graeme Radford-Smith; Warwick Selby; Michael J Johnston; Rodney Woods; P Ross Elliott; Sally J Bell; Steven J Brown; William R Connell; Andrew S Day; Paul V Desmond; Richard B Gearry
Journal:  Gastroenterology       Date:  2015-01-22       Impact factor: 22.682

6.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

7.  Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease.

Authors:  Benjamin Pariente; Jean-Yves Mary; Silvio Danese; Yehuda Chowers; Peter De Cruz; Geert D'Haens; Edward V Loftus; Edouard Louis; Julian Panés; Jürgen Schölmerich; Stefan Schreiber; Maurizio Vecchi; Julien Branche; David Bruining; Gionata Fiorino; Matthias Herzog; Michael A Kamm; Amir Klein; Maïté Lewin; Paul Meunier; Ingrid Ordas; Ulrike Strauch; Gian-Eugenio Tontini; Anne-Marie Zagdanski; Cristiana Bonifacio; Jordi Rimola; Maria Nachury; Christophe Leroy; William Sandborn; Jean-Frédéric Colombel; Jacques Cosnes
Journal:  Gastroenterology       Date:  2014-09-21       Impact factor: 22.682

8.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.

Authors:  Kathrine Frey Frøslie; Jørgen Jahnsen; Bjørn A Moum; Morten H Vatn
Journal:  Gastroenterology       Date:  2007-06-02       Impact factor: 22.682

9.  Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.

Authors:  Stephane Nancey; Gilles Boschetti; Driffa Moussata; Eddy Cotte; Julie Peyras; Charlotte Cuerq; Julie Haybrard; Anne-Laure Charlois; Anne Mialon; Marion Chauvenet; Karine Stroeymeyt; Dominique Kaiserlian; Jocelyne Drai; Bernard Flourié
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

10.  Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health.

Authors:  Laurent Peyrin-Biroulet; Alarcos Cieza; William J Sandborn; Michaela Coenen; Yehuda Chowers; Toshifumi Hibi; Nenad Kostanjsek; Gerold Stucki; Jean-Frédéric Colombel
Journal:  Gut       Date:  2011-06-05       Impact factor: 23.059

View more
  2 in total

1.  The Influence of Aerobic Type Exercise on Active Crohn's Disease Patients: The Incidence of an Elite Athlete.

Authors:  Konstantinos Papadimitriou
Journal:  Healthcare (Basel)       Date:  2022-04-12

2.  Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.

Authors:  Viktoria Bergqvist; Johanna Holmgren; Daniel Klintman; Jan Marsal
Journal:  Aliment Pharmacol Ther       Date:  2022-04-25       Impact factor: 9.524

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.